

For Immediate Release

CyGenics Awarded Another Patent

Stem cell therapy leader awarded patent on its Cell Culture Spinner Flasks

Key Points:

- Granted new patent for its starwheel cell culture spinner flasks.
- Wide pharmaceutical research and production applications.
- Six patents in the CyGenics group.

16th March 2006 – Leading cell therapy services company CyGenics Ltd. (ASX: CYN) announced that its US-based subsidiary, Cytomatrix LLC, had been granted US Patent 6991933, Cell Culture Spinner Flasks. This patent adds to the five already granted to the CyGenics group. A number of other patents are pending.

The patent is for the company's unique starwheel cell culture spinner flasks. These flasks provide an enhanced system for cell growth and improved secreted product yield by improving materials transfer via passive perfusion. The system can produce high concentrations of cells that can be used as targets for extraneous agent interaction such as viruses or stimulating compounds. Cells or modified cells grown in the system can be used to produce higher levels of secreted products while minimizing downstream processing.

The flasks are currently being used for research purposes and under license for small scale manufacture of specialized products.

The flasks are currently sold through the products arm of CyGenics, Cell Sciences and through a distributor in the US, BioMedical Resources, Northboro MA.

"Our system optimises research and small volume manufacture with the added benefit of a linearly scaleable path toward large volume manufacture system design," said Dr John Flickinger, President of Cytomatrix. "A fully loaded system with a working volume of approximately 500 ml will produce at the level of a 5 L bioreactor on a small and easily manipulated foot print."

"This grant of patent reinforces CyGenics' intellectual property proposition, and protects us as we introduce these flasks into more markets around the world," said Steven Fang, CEO CyGenics. "I anticipate that this unique spinner system, employing our patented three-dimensional cellular growth scaffold, will continue to be well received by researchers and pharmaceutical companies."

About CyGenics

CyGenics is a cell therapy services company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates five subsidiaries: Singapore-based CordLife and Australia-based BioCell (tissue banking services, in particular, cord blood banking), Cell Sciences (consumable cell culture products), Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

General Inquiries

Steven Fang, Group CEO, CyGenics Ltd Ph : +61 (0)400 933 243 Email: steven.fang@cygenics.com	Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
--	--

Media Inquiries

Rebecca Piercy, Buchan Consulting Ph: +61 (0)2 9287 2800 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au	Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
---	--